A population analysis of prescriptions for asthma medications during pregnancy - 27/02/13
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Abstract |
Background |
It is important to control asthma during pregnancy. However, some studies indicate that women stop or change their asthma medications when they become pregnant.
Objective |
We used a population database to analyze changes in prescriptions for asthma medications to patients before, during, and after pregnancy.
Methods |
We collected information from a pregnancy database that is part of the population-based pharmacy prescription InterAction Database from the northern Netherlands. Our study cohort comprised 25,709 pregnancies for which prescription data were available. We collected data over a study period of 1 year before pregnancy until 6 months after birth and analyzed data from pregnant women who received at least 1 prescription for asthma medication during the study period (n = 2072), identifying all prescriptions for asthma medication and oral corticosteroids.
Results |
Prescriptions for asthma medications did not change during pregnancies from 1994-2003. However, during the 2004-2009 period, there was a significant decrease (P = .017) in prescriptions for asthma medications during the first months of pregnancy compared with the months before pregnancy, especially prescriptions of long-acting bronchodilators. Although most asthma prescriptions continued throughout pregnancy, prescriptions for controller therapies were reduced by 30% during the first months of pregnancy.
Conclusions |
Many women stop or reduce their use of asthma medications when they become pregnant. Strategies to safely control asthma during pregnancy are needed.
Le texte complet de cet article est disponible en PDF.Key words : Drug use, asthma medication, asthma guidelines, pregnancy
Abbreviations used : IADB, NHG
Plan
Disclosure of potential conflict of interest: L. T. W. de Jong–van den Berg is a board member for the ISPE and has received one or more grants from or has one or more grants pending with PROTECT and EUROmediCAT. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 3
P. 711-717 - mars 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?